Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 211

1.

Total Methionine Restriction Treatment of Cancer.

Hoffman RM, Kokkinakis DM, Frenkel EP.

Methods Mol Biol. 2019;1866:163-171. doi: 10.1007/978-1-4939-8796-2_13.

PMID:
30725415
2.

Metagenomic Shotgun Sequencing and Unbiased Metabolomic Profiling Identify Specific Human Gut Microbiota and Metabolites Associated with Immune Checkpoint Therapy Efficacy in Melanoma Patients.

Frankel AE, Coughlin LA, Kim J, Froehlich TW, Xie Y, Frenkel EP, Koh AY.

Neoplasia. 2017 Oct;19(10):848-855. doi: 10.1016/j.neo.2017.08.004. Epub 2017 Sep 15.

3.

Academic Cancer Center Phase I Program Development.

Frankel AE, Flaherty KT, Weiner GJ, Chen R, Azad NS, Pishvaian MJ, Thompson JA, Taylor MH, Mahadevan D, Lockhart AC, Vaishampayan UN, Berlin JD, Smith DC, Sarantopoulos J, Riese M, Saleh MN, Ahn C, Frenkel EP.

Oncologist. 2017 Apr;22(4):369-374. doi: 10.1634/theoncologist.2016-0409. Epub 2017 Mar 17.

4.

Molecular heterogeneity in adjacent cells in triple-negative breast cancer.

Huebschman ML, Lane NL, Liu H, Sarode VR, Devlin JL, Frenkel EP.

Breast Cancer (Dove Med Press). 2015 Aug 11;7:231-7. doi: 10.2147/BCTT.S87041. eCollection 2015.

5.

Systematic siRNA Screen Unmasks NSCLC Growth Dependence by Palmitoyltransferase DHHC5.

Tian H, Lu JY, Shao C, Huffman KE, Carstens RM, Larsen JE, Girard L, Liu H, Rodriguez-Canales J, Frenkel EP, Wistuba II, Minna JD, Hofmann SL.

Mol Cancer Res. 2015 Apr;13(4):784-94. doi: 10.1158/1541-7786.MCR-14-0608. Epub 2015 Jan 8.

6.

In-vivo evaluation of human recombinant Co-arginase against A375 melanoma xenografts.

Agrawal V, Woo JH, Mauldin JP, Stone EM, Meininger CJ, Jo C, Kleypas K, Frenkel EP, Frankel AE.

Melanoma Res. 2014 Dec;24(6):556-67. doi: 10.1097/CMR.0000000000000119.

PMID:
25304236
7.

Preclinical antitumor activity of S-222611, an oral reversible tyrosine kinase inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2.

Tanaka H, Hirata M, Shinonome S, Wada T, Iguchi M, Dohi K, Inoue M, Ishioka Y, Hojo K, Yamada T, Sugimoto T, Masuno K, Nezasa K, Sato N, Matsuo K, Yonezawa S, Frenkel EP, Shichijo M.

Cancer Sci. 2014 Aug;105(8):1040-8. doi: 10.1111/cas.12449.

8.

Versatile immunomagnetic nanocarrier platform for capturing cancer cells.

Wu CH, Huang YY, Chen P, Hoshino K, Liu H, Frenkel EP, Zhang JX, Sokolov KV.

ACS Nano. 2013 Oct 22;7(10):8816-23. doi: 10.1021/nn403281e. Epub 2013 Sep 12.

9.

Using iron oxide nanoparticles to diagnose CNS inflammatory diseases and PCNSL.

Farrell BT, Hamilton BE, Dósa E, Rimely E, Nasseri M, Gahramanov S, Lacy CA, Frenkel EP, Doolittle ND, Jacobs PM, Neuwelt EA.

Neurology. 2013 Jul 16;81(3):256-63. doi: 10.1212/WNL.0b013e31829bfd8f. Epub 2013 Jun 14.

10.

Mutations in GATA2 cause human NK cell deficiency with specific loss of the CD56(bright) subset.

Mace EM, Hsu AP, Monaco-Shawver L, Makedonas G, Rosen JB, Dropulic L, Cohen JI, Frenkel EP, Bagwell JC, Sullivan JL, Biron CA, Spalding C, Zerbe CS, Uzel G, Holland SM, Orange JS.

Blood. 2013 Apr 4;121(14):2669-77. doi: 10.1182/blood-2012-09-453969. Epub 2013 Jan 30.

11.

Immunomagnetic nanoscreening of circulating tumor cells with a motion controlled microfluidic system.

Huang YY, Hoshino K, Chen P, Wu CH, Lane N, Huebschman M, Liu H, Sokolov K, Uhr JW, Frenkel EP, Zhang JXJ.

Biomed Microdevices. 2013 Aug;15(4):673-681. doi: 10.1007/s10544-012-9718-8.

12.

Molecular profiling of individual tumor cells by hyperspectral microscopic imaging.

Uhr JW, Huebschman ML, Frenkel EP, Lane NL, Ashfaq R, Liu H, Rana DR, Cheng L, Lin AT, Hughes GA, Zhang XJ, Garner HR.

Transl Res. 2012 May;159(5):366-75. doi: 10.1016/j.trsl.2011.08.003. Epub 2011 Sep 3.

13.

Targeting methionine auxotrophy in cancer: discovery & exploration.

Agrawal V, Alpini SE, Stone EM, Frenkel EP, Frankel AE.

Expert Opin Biol Ther. 2012 Jan;12(1):53-61. doi: 10.1517/14712598.2012.636349. Epub 2011 Nov 5. Review.

PMID:
22171665
14.

Incidence of isolated heparin-induced thrombocytopenia and risk of thrombosis by IgG-specific anti-PF4/heparin ELISA.

Radaideh SM, Frenkel EP, Dowell JE, Sarode R, Shen YM.

Clin Appl Thromb Hemost. 2012 Mar-Apr;18(2):215-7. doi: 10.1177/1076029611423389. Epub 2011 Nov 8.

PMID:
22067544
15.

Microchip-based immunomagnetic detection of circulating tumor cells.

Hoshino K, Huang YY, Lane N, Huebschman M, Uhr JW, Frenkel EP, Zhang X.

Lab Chip. 2011 Oct 21;11(20):3449-57. doi: 10.1039/c1lc20270g. Epub 2011 Aug 24.

16.

The paradoxical effect of bevacizumab in the therapy of malignant gliomas.

Thompson EM, Frenkel EP, Neuwelt EA.

Neurology. 2011 Jan 4;76(1):87-93. doi: 10.1212/WNL.0b013e318204a3af.

17.

Upregulation of TRAG3 gene in urothelial carcinoma of the bladder.

Karam JA, Huang S, Fan J, Stanfield J, Schultz RA, Pong RC, Sun X, Mason RP, Xie XJ, Niu G, Chen X, Frenkel EP, Sagalowsky AI, Hsieh JT.

Int J Cancer. 2011 Jun 15;128(12):2823-32. doi: 10.1002/ijc.25631. Epub 2010 Oct 26.

18.

Histone deacetylase inhibitor romidepsin enhances anti-tumor effect of erlotinib in non-small cell lung cancer (NSCLC) cell lines.

Zhang W, Peyton M, Xie Y, Soh J, Minna JD, Gazdar AF, Frenkel EP.

J Thorac Oncol. 2009 Feb;4(2):161-6. doi: 10.1097/JTO.0b013e318194fae7.

19.

Phase I dose escalation study with irinotecan, capecitabine, epirubicin, and granulocyte colony-stimulating factor support for patients with solid malignancies.

Becerra CR, Verma UN, Tran HT, Tavana D, Williams NS, Frenkel EP.

Am J Clin Oncol. 2008 Jun;31(3):219-25. doi: 10.1097/COC.0b013e31815a438f.

PMID:
18525298
20.
21.

Acquired platelet dysfunction.

Shen YM, Frenkel EP.

Hematol Oncol Clin North Am. 2007 Aug;21(4):647-61, vi. Review.

PMID:
17666283
22.

Comparison of a rapid platelet function assay--Verify Now Aspirin--with whole blood impedance aggregometry for the detection of aspirin resistance.

Dyszkiewicz-Korpanty AM, Kim A, Burner JD, Frenkel EP, Sarode R.

Thromb Res. 2007;120(4):485-8. Epub 2007 Jan 16. No abstract available.

PMID:
17229458
23.

Efficacy of sequential treatment of HCT116 colon cancer monolayers and xenografts with docetaxel, flavopiridol, and 5-fluorouracil.

Guo J, Zhou AW, Fu YC, Verma UN, Tripathy D, Frenkel EP, Becerra CR.

Acta Pharmacol Sin. 2006 Oct;27(10):1375-81.

24.

Methylation of apoptosis related genes in the pathogenesis and prognosis of prostate cancer.

Suzuki M, Shigematsu H, Shivapurkar N, Reddy J, Miyajima K, Takahashi T, Gazdar AF, Frenkel EP.

Cancer Lett. 2006 Oct 28;242(2):222-30. Epub 2006 Feb 3. Retraction in: Cancer Lett. 2015 Apr 28;360(1):87.

PMID:
16458425
25.
26.

DNA methylation-associated inactivation of TGFbeta-related genes DRM/Gremlin, RUNX3, and HPP1 in human cancers.

Suzuki M, Shigematsu H, Shames DS, Sunaga N, Takahashi T, Shivapurkar N, Iizasa T, Frenkel EP, Minna JD, Fujisawa T, Gazdar AF.

Br J Cancer. 2005 Oct 31;93(9):1029-37. Retraction in: Br J Cancer. 2013 Dec 10;109(12):3132.

27.

IkappaB kinase alpha regulates subcellular distribution and turnover of cyclin D1 by phosphorylation.

Kwak YT, Li R, Becerra CR, Tripathy D, Frenkel EP, Verma UN.

J Biol Chem. 2005 Oct 7;280(40):33945-52. Epub 2005 Aug 15. Erratum in: J Biol Chem. 2005 Nov 18;280(46):38888.

28.
29.

The direct thrombin inhibitors: their role and use for rational anticoagulation.

Frenkel EP, Shen YM, Haley BB.

Hematol Oncol Clin North Am. 2005 Feb;19(1):119-45, vi-vii. Review.

PMID:
15639111
30.

Unfractionated heparin, low molecular weight heparins, and pentasaccharide: basic mechanism of actions, pharmacology, and clinical use.

Bick RL, Frenkel EP, Walenga J, Fareed J, Hoppensteadt DA.

Hematol Oncol Clin North Am. 2005 Feb;19(1):1-51, v. Review.

PMID:
15639107
31.

Circulating tumor cells in patients with breast cancer dormancy.

Meng S, Tripathy D, Frenkel EP, Shete S, Naftalis EZ, Huth JF, Beitsch PD, Leitch M, Hoover S, Euhus D, Haley B, Morrison L, Fleming TP, Herlyn D, Terstappen LW, Fehm T, Tucker TF, Lane N, Wang J, Uhr JW.

Clin Cancer Res. 2004 Dec 15;10(24):8152-62.

32.

MIB1 labeling index as an indicator of chemoresponse in carcinoma of the breast.

Sharma S, Saboorian HM, Frawley WH, Frenkel EP, Haley BB, Ashfaq R.

Appl Immunohistochem Mol Morphol. 2004 Dec;12(4):290-5.

PMID:
15536327
33.

PEGylation confers greatly extended half-life and attenuated immunogenicity to recombinant methioninase in primates.

Yang Z, Wang J, Lu Q, Xu J, Kobayashi Y, Takakura T, Takimoto A, Yoshioka T, Lian C, Chen C, Zhang D, Zhang Y, Li S, Sun X, Tan Y, Yagi S, Frenkel EP, Hoffman RM.

Cancer Res. 2004 Sep 15;64(18):6673-8.

34.

Circulating half-life of PEGylated recombinant methioninase holoenzyme is highly dose dependent on cofactor pyridoxal-5'-phosphate.

Yang Z, Sun X, Li S, Tan Y, Wang X, Zhang N, Yagi S, Takakura T, Kobayashi Y, Takimoto A, Yoshioka T, Suginaka A, Frenkel EP, Hoffman RM.

Cancer Res. 2004 Aug 15;64(16):5775-8.

35.

Thrombosis and a hypercoagulable state in HIV-infected patients.

Shen YM, Frenkel EP.

Clin Appl Thromb Hemost. 2004 Jul;10(3):277-80. Review.

PMID:
15247986
36.

Enhanced chemosensitivity to irinotecan by RNA interference-mediated down-regulation of the nuclear factor-kappaB p65 subunit.

Guo J, Verma UN, Gaynor RB, Frenkel EP, Becerra CR.

Clin Cancer Res. 2004 May 15;10(10):3333-41.

37.

Pharmacokinetics, methionine depletion, and antigenicity of recombinant methioninase in primates.

Yang Z, Wang J, Yoshioka T, Li B, Lu Q, Li S, Sun X, Tan Y, Yagi S, Frenkel EP, Hoffman RM.

Clin Cancer Res. 2004 Mar 15;10(6):2131-8.

38.

Molecular detection of noninvasive and invasive bladder tumor tissues and exfoliated cells by aberrant promoter methylation of laminin-5 encoding genes.

Sathyanarayana UG, Maruyama R, Padar A, Suzuki M, Bondaruk J, Sagalowsky A, Minna JD, Frenkel EP, Grossman HB, Czerniak B, Gazdar AF.

Cancer Res. 2004 Feb 15;64(4):1425-30.

39.

Aberrant promoter methylation of laminin-5-encoding genes in prostate cancers and its relationship to clinicopathological features.

Sathyanarayana UG, Padar A, Suzuki M, Maruyama R, Shigematsu H, Hsieh JT, Frenkel EP, Gazdar AF.

Clin Cancer Res. 2003 Dec 15;9(17):6395-400.

40.

In vivo efficacy of recombinant methioninase is enhanced by the combination of polyethylene glycol conjugation and pyridoxal 5'-phosphate supplementation.

Sun X, Yang Z, Li S, Tan Y, Zhang N, Wang X, Yagi S, Yoshioka T, Takimoto A, Mitsushima K, Suginaka A, Frenkel EP, Hoffman RM.

Cancer Res. 2003 Dec 1;63(23):8377-83.

41.

Inactivation of cyclin D2 gene in prostate cancers by aberrant promoter methylation.

Padar A, Sathyanarayana UG, Suzuki M, Maruyama R, Hsieh JT, Frenkel EP, Minna JD, Gazdar AF.

Clin Cancer Res. 2003 Oct 15;9(13):4730-4.

42.
43.

Heparin-induced thrombocytopenia, paradoxical thromboembolism, and other adverse effects of heparin-type therapy.

Walenga JM, Frenkel EP, Bick RL.

Hematol Oncol Clin North Am. 2003 Feb;17(1):259-82, viii-ix. Review.

PMID:
12627671
44.

Hyperhomocysteinemia and thrombosis.

Lee R, Frenkel EP.

Hematol Oncol Clin North Am. 2003 Feb;17(1):85-102. Review.

PMID:
12627664
45.

Sticky platelet syndrome and thrombocythemia.

Frenkel EP, Mammen EF.

Hematol Oncol Clin North Am. 2003 Feb;17(1):63-83. Review.

PMID:
12627663
46.

Cobalamin profiles in patients after urinary diversion.

Sagalowsky AI, Frenkel EP.

J Urol. 2002 Apr;167(4):1696-700.

PMID:
11912390
47.

Aneusomy 17 in breast cancer: its role in HER-2/neu protein expression and implication for clinical assessment of HER-2/neu status.

Wang S, Hossein Saboorian M, Frenkel EP, Haley BB, Siddiqui MT, Gokaslan S, Hynan L, Ashfaq R.

Mod Pathol. 2002 Feb;15(2):137-45.

48.

Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features.

Maruyama R, Toyooka S, Toyooka KO, Virmani AK, Zöchbauer-Müller S, Farinas AJ, Minna JD, McConnell J, Frenkel EP, Gazdar AF.

Clin Cancer Res. 2002 Feb;8(2):514-9.

49.

Enhanced transgene expression in androgen independent prostate cancer gene therapy by taxane chemotherapeutic agents.

Li Y, Okegawa T, Lombardi DP, Frenkel EP, Hsieh JT.

J Urol. 2002 Jan;167(1):339-46.

PMID:
11743353
50.

Supplemental Content

Loading ...
Support Center